 Source: Shutterstock Spero Therapeutics NASDAQ: SPRO stock is climbing higher on Wednesday thanks to positive feedback from the FDA. That concerns plans to resubmit tebipenem HBr for the treatment of complicated urinary tract infection cUTI. 